Intensity Therapeutics, Inc. Common stock Market Cap ($9.14 Million)
Market Cap & Net Worth: Intensity Therapeutics, Inc. Common stock (INTS)
Intensity Therapeutics, Inc. Common stock market cap. Intensity Therapeutics, Inc. Common stock (NASDAQ:INTS) has a market capitalization of $9.14 Million ($9.14 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27168 globally and #5646 in its home market, demonstrating a 5.62% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Intensity Therapeutics, Inc. Common stock's stock price $3.38 by its total outstanding shares 2702820 (2.70 Million). Also see INTS cash flow metrics for how efficiently the company converts equity into cash flow.
Intensity Therapeutics, Inc. Common stock Market Cap History (2023–2026)
Intensity Therapeutics, Inc. Common stock market cap history from 2023 to 2026. Data shows change from $23.16 Million to $9.14 Million (-15.58% CAGR). Check Intensity Therapeutics, Inc. Common stoc (INTS) share price today for real-time trading data and today's change.
Index Memberships
Intensity Therapeutics, Inc. Common stock is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #765 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2486 of 3165 |
Weight: Intensity Therapeutics, Inc. Common stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Intensity Therapeutics, Inc. Common stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Intensity Therapeutics, Inc. Common stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of Intensity Therapeutics, Inc. Common stoc to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of INTS by Market Capitalization
Companies near Intensity Therapeutics, Inc. Common stock in the global market cap rankings as of November 4, 2026. Also see INTS current and non-current assets for a full breakdown of the balance sheet.
Key companies related to Intensity Therapeutics, Inc. Common stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Intensity Therapeutics, Inc. Common stock (2023–2026)
Market capitalization of Intensity Therapeutics, Inc. Common stock from 2023 to today. Between 2023 and today, Intensity Therapeutics, Inc. Common stock's market cap moved from $23.16 Million to $ 9.14 Million, with a yearly change of -15.58%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $9.14 Million | +723.99% |
| 2025 | $1.11 Million | -76.69% |
| 2024 | $4.76 Million | -79.46% |
| 2023 | $23.16 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Intensity Therapeutics, Inc. Common stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.14 Million USD |
| MoneyControl | $9.14 Million USD |
| MarketWatch | $9.14 Million USD |
| marketcap.company | $9.14 Million USD |
| Reuters | $9.14 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Intensity Therapeutics, Inc. Common stock
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is… Read more